239 related articles for article (PubMed ID: 26341737)
21. Constitutively active androgen receptor supports the metastatic phenotype of endocrine-resistant hormone receptor-positive breast cancer.
Bahnassy S; Thangavel H; Quttina M; Khan AF; Dhanyalayam D; Ritho J; Karami S; Ren J; Bawa-Khalfe T
Cell Commun Signal; 2020 Sep; 18(1):154. PubMed ID: 32948192
[TBL] [Abstract][Full Text] [Related]
22. The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance.
Wong C; Chen S
J Steroid Biochem Mol Biol; 2012 Sep; 131(3-5):83-92. PubMed ID: 22265958
[TBL] [Abstract][Full Text] [Related]
23. Non-canonical AR activity facilitates endocrine resistance in breast cancer.
Chia K; Milioli H; Portman N; Laven-Law G; Coulson R; Yong A; Segara D; Parker A; Caldon CE; Deng N; Swarbrick A; Tilley WD; Hickey TE; Lim E
Endocr Relat Cancer; 2019 Feb; 26(2):251-264. PubMed ID: 30557851
[TBL] [Abstract][Full Text] [Related]
24. IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer in vivo by JAK/STAT-mediated induction of p21.
Lui AJ; Geanes ES; Ogony J; Behbod F; Marquess J; Valdez K; Jewell W; Tawfik O; Lewis-Wambi J
Cancer Lett; 2017 Jul; 399():29-43. PubMed ID: 28411130
[TBL] [Abstract][Full Text] [Related]
25. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.
Hiscox S; Morgan L; Green TP; Barrow D; Gee J; Nicholson RI
Breast Cancer Res Treat; 2006 Jun; 97(3):263-74. PubMed ID: 16333527
[TBL] [Abstract][Full Text] [Related]
26. Amplification and overexpression of prosaposin in prostate cancer.
Koochekpour S; Zhuang YJ; Beroukhim R; Hsieh CL; Hofer MD; Zhau HE; Hiraiwa M; Pattan DY; Ware JL; Luftig RB; Sandhoff K; Sawyers CL; Pienta KJ; Rubin MA; Vessella RL; Sellers WR; Sartor O
Genes Chromosomes Cancer; 2005 Dec; 44(4):351-64. PubMed ID: 16080200
[TBL] [Abstract][Full Text] [Related]
27. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
28. Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer.
Jia Y; Song Y; Dong G; Hao C; Zhao W; Li S; Tong Z
Sci Rep; 2019 Sep; 9(1):12939. PubMed ID: 31506496
[TBL] [Abstract][Full Text] [Related]
29. Prosaposin is a novel androgen-regulated gene in prostate cancer cell line LNCaP.
Koochekpour S; Lee TJ; Wang R; Sun Y; Delorme N; Hiraiwa M; Grabowski GA; Culig Z; Minokadeh A
J Cell Biochem; 2007 Jun; 101(3):631-41. PubMed ID: 17171640
[TBL] [Abstract][Full Text] [Related]
30. Metastatic progression with resistance to aromatase inhibitors is driven by the steroid receptor coactivator SRC-1.
McBryan J; Theissen SM; Byrne C; Hughes E; Cocchiglia S; Sande S; O'Hara J; Tibbitts P; Hill AD; Young LS
Cancer Res; 2012 Jan; 72(2):548-59. PubMed ID: 22108824
[TBL] [Abstract][Full Text] [Related]
31. Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors.
Varešlija D; McBryan J; Fagan A; Redmond AM; Hao Y; Sims AH; Turnbull A; Dixon JM; Ó Gaora P; Hudson L; Purcell S; Hill AD; Young LS
Clin Cancer Res; 2016 Jun; 22(11):2765-77. PubMed ID: 26763249
[TBL] [Abstract][Full Text] [Related]
32. Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.
Elias D; Vever H; Lænkholm AV; Gjerstorff MF; Yde CW; Lykkesfeldt AE; Ditzel HJ
Oncogene; 2015 Apr; 34(15):1919-27. PubMed ID: 24882577
[TBL] [Abstract][Full Text] [Related]
33. Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Itoh T; Karlsberg K; Kijima I; Yuan YC; Smith D; Ye J; Chen S
Mol Cancer Res; 2005 Apr; 3(4):203-18. PubMed ID: 15831674
[TBL] [Abstract][Full Text] [Related]
34. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
[TBL] [Abstract][Full Text] [Related]
35. Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients.
Lundin KB; Henningson M; Hietala M; Ingvar C; Rose C; Jernström H
Br J Cancer; 2011 Nov; 105(11):1676-83. PubMed ID: 22033271
[TBL] [Abstract][Full Text] [Related]
36. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
Berstein LM; Yue W; Wang JP; Santen RJ
Breast Cancer Res Treat; 2011 Jul; 128(1):109-17. PubMed ID: 20683653
[TBL] [Abstract][Full Text] [Related]
37. Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort.
Elebro K; Borgquist S; Simonsson M; Markkula A; Jirström K; Ingvar C; Rose C; Jernström H
Clin Cancer Res; 2015 Aug; 21(16):3640-50. PubMed ID: 25904752
[TBL] [Abstract][Full Text] [Related]
38. A gene transcription signature associated with hormone independence in a subset of both breast and prostate cancers.
Creighton CJ
BMC Genomics; 2007 Jun; 8():199. PubMed ID: 17598908
[TBL] [Abstract][Full Text] [Related]
39. Endocrine therapy and other targeted therapies for metastatic breast cancer.
Hussain SA; Palmer DH; Moon S; Rea DW
Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
[TBL] [Abstract][Full Text] [Related]
40. Effects of steroidal aromatase inhibitors on sensitive and resistant breast cancer cells: aromatase inhibition and autophagy.
Amaral C; Varela C; Azevedo M; da Silva ET; Roleira FM; Chen S; Correia-da-Silva G; Teixeira N
J Steroid Biochem Mol Biol; 2013 May; 135():51-9. PubMed ID: 23318878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
